Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey

Century Therapeutics announced a significant expansion of its operational and laboratory space in Philadelphia, as well as progress on its manufacturing facility in Branchburg, NJ, paving the way for a strong technical foundation as the company scales up its in-house research and development capabilities.
[Century Therapeutics (Cision US Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership for MVX-ONCO-2 Cancer Immunotherapy

MaxiVAX SA and Minaris Regenerative Medicine GmbH have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such as chordoma, head and neck, and other solid tumors.
[MaxiVAX SA]
Press Release
Bookmark

No account yet? Register

0
Share

Evan Snyder Named Fellow of the American Institute for Medical and Biological Engineering

The American Institute for Medical and Biological Engineering has elected to its College of Fellows Evan Snyder, professor and founding director of the Center for Stem Cells and Regenerative Medicine at Sanford Burnham Prebys Medical Discovery Institute.
[Sanford Burnham Prebys Medical Discovery Institute]
Press Release
Bookmark

No account yet? Register

0
Share

Florica Therapeutics, Inc. Awarded Competitive Grant from the National Science Foundation to Study Brain-Immune Axis in COVID-19

Florica Therapeutics, Inc. has been awarded a National Science Foundation Small Business Innovation Research grant for $255,678 to work on the Hypothalamus Stem Cell Exosomes for Treatment of COVID-19 project.
[Florica Therapeutics, Inc. (Businesswire, Inc)]
Press Release
Bookmark

No account yet? Register

0
Share

A Molecular Biologist Has Been Awarded Funding to Support a New Method of Research into Blood Cancer

Dr. Salvatore Papa, an Assistant Professor in Cancer Research at the University of Leeds, has been awarded Leukaemia & Myeloma Research UK’s research grant to continue his specialist studies into examining how the accumulation of mutated proteins in certain blood cancer cells allows them to multiply repeatedly.
[Charity Today]
Press Release
Bookmark

No account yet? Register

0
Share

Therapeutic Solutions International Uses StemVacs™ Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cells

Therapeutic Solutions International, Inc., reported novel data and filing of a patent application demonstrating that StemVacs™ cells carrying proprietary sequences from the cancer-specific antigen Brother of the Regulator of Imprinted Sites, were able to elicit the generation of T cells capable of selectively killing cancer stem cells.
[Therapeutic Solutions International, Inc. (PR Newswire)]
Press Release
Bookmark

No account yet? Register

0
Share

JDRF Announces New Center of Excellence in New England to Advance Type 1 Diabetes Research

JDRF announced, in collaboration with the Harvard Stem Cell Institute, the launch of the JDRF Center of Excellence in New England.
[JDRF (PR Newswire, LLC)]
Press Release
Bookmark

No account yet? Register

0
Share

Rousselot Biomedical, a Darling Ingredients Brand, Joins European ENLIGHT Project to Develop a 3D Living Model of Pancreatic Tissue

Darling Ingredients, Inc. announced that its Rousselot Biomedical brand is joining the European project ENLIGHT. Researchers from academic centers and leading industries across Europe are joining forces to develop a living model of the pancreas to enable better testing of diabetes medication.
[Darling Ingredients, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-COVID-19

Mesoblast Limited has treated the first two children with their MSC product candidate remestemcel-L for life-threatening multisystem inflammatory syndrome (MIS-C) associated with COVID-19.MIS-C, a potentially life-threatening inflammatory condition which involves multiple critical organs and their vasculature, is associated with prior rather than active COVID-19 infection.
[Mesoblast, Ltd.]
Press Release
Bookmark

No account yet? Register

0
Share

FibroGenesis Reports Positive Preclinical Data in Pancreatic and Breast Cancer Using “Universal Acting” Fibroblast Based Immunotherapy

FibroGenesis announced new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer.
[FibroGenesis]
Press Release
Bookmark

No account yet? Register

0
Share

Theralink® Technologies Moves Closer toward Changing the Standard of Care for All Women Newly Diagnosed with HER2+ Breast Cancer

Theralink Technologies, Inc. was named commercial provider of its patented Reverse Phase Protein Array technology for breast cancer patients, if the proposed study has a positive outcome.
[Theralink Technologies, Inc. (PR Newswire, LLC)]
Press Release
Bookmark

No account yet? Register

0
Share
Share